ARTICLE | Company News
OSI deal
May 23, 2005 7:00 AM UTC
OSIP's Prosidion diabetes and obesity business unit granted an undisclosed pharmaceutical company non-exclusive worldwide rights to its IP covering inhibitors of dipeptidyl peptidase-4 (DPP-4) to tre...